Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE , Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medi...
Impel Pharmaceuticals (NASDAQ: IMPL ) stock is on the rise Friday after the company announced an amended credit agreement with Oaktree Fund Administration. This new credit agreement has Impel Pharmaceuticals obtaining a loan of $121.5 million from new and existing investors.
Impel Pharmaceuticals (NASDAQ: IMPL ) stock is falling on Wednesday after the biopharmaceutical company failed to file its earnings report on time. According to a filing with the Securities and Exchange Commission (SEC), several issues kept Impel Pharmaceuticals from filing in a timely manner.
Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Operator Good morning, ladies and gentlemen, and welcome to Impel Pharmaceuticals Third Quarter 20...
SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Adrian Adams, Chairman and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology ...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.